Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Sanofi (EURONEXT: SAN and NYSE: SNY) announced today new results from sub-analyses of the First Basal INsulin Evaluation in Asia (FINE Asia) Registry study,[1] and the Cardiovascular Risk Evaluation in People with Type 2 Diabetes on Insulin Therapy (CREDIT) study.[2]
FINE Asia was a six-month, 11-Asian-country prospective observational study to assess the effect of 'time to basal insulin initiation' on glycemic control and co-morbidities in insulin-na?ve adults with type 2 diabetes (T2D), uncontrolled on oral antidiabetic medications. Patients (n=2,673) were grouped according to duration of diabetes since diagnosis (<6y; 6-11y; or ≥12y). Results showed that people with T2D who are initiated on insulin therapy earlier in the progression of their diabetes achieved greater glycemic control.
Across the FINE Asia sub-analysis groups, baseline HbA1c was similar (9.8%), and the patients who had the shortest time to insulin initiation (71-79% insulin glargine users) showed the greatest (mean) improvement in HbA1c at 6 months: <6y: 7.5%; 6-11y: 7.8%; ≥12y: 7.9% (p<0.001 for all three groups).
http://www.prnewswire.co.uk/cgi/news/release?id=341879
FINE Asia was a six-month, 11-Asian-country prospective observational study to assess the effect of 'time to basal insulin initiation' on glycemic control and co-morbidities in insulin-na?ve adults with type 2 diabetes (T2D), uncontrolled on oral antidiabetic medications. Patients (n=2,673) were grouped according to duration of diabetes since diagnosis (<6y; 6-11y; or ≥12y). Results showed that people with T2D who are initiated on insulin therapy earlier in the progression of their diabetes achieved greater glycemic control.
Across the FINE Asia sub-analysis groups, baseline HbA1c was similar (9.8%), and the patients who had the shortest time to insulin initiation (71-79% insulin glargine users) showed the greatest (mean) improvement in HbA1c at 6 months: <6y: 7.5%; 6-11y: 7.8%; ≥12y: 7.9% (p<0.001 for all three groups).
http://www.prnewswire.co.uk/cgi/news/release?id=341879